

## Navicixizumab

Cat. No.:	HY-P99377
CAS No.:	1638338-43-8
Target:	Notch
Pathway:	Neuronal Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with <a href="#">Paclitaxel</a> (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM)
<b>In Vitro</b>	Navicixizumab (0-100 μM) reduces proliferation of human endothelial cells in the presence of hVEGF <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol*. 2022 Aug 10;40(23):2568-2577.
- [2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. *Ann Transl Med*. 2020 Dec;8(24):1705.
- [3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. *Mol Cancer Ther* (2015) 14 (12\_Supplement\_2): C164.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA